All In Biotech

Drug Trial Radar · NCT05382091

Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons

A Phase II Multi-Center Safety Study Examining the Use of the O'Neil Long Acting Naltrexone Implant (OLANI) in Opioid Dependent Persons Receiving Repeat Dosing

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jul 1, 2029

Study completion Jul 1, 2030

Sponsor

Lead sponsor
Go Medical Industries Pty LtdIndustry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA); New York State Psychiatric Institute; Columbia University; The Emmes Company, LLC; University at Buffalo
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and efficacy of the O'Neil Long Acting Naltrexone Implant (OLANI) in persons with opioid dependency who are seeking relapse-prevention treatment. All participants will be treated in an open label manner. No randomization will occur. The OLANI is a long-acting biodegradable form of naltrexone which is implanted in the abdominal region. It is hypothesized that the OLANI will produce blood levels sufficient to block the effects of opioids for an extended period allowing patients to engage in psychosocial treatment and recovery over the long term. After the initial set of implants, participants will be offered 3 sets of single implants 13 weeks, each with an acceptable window of 12-16 weeks after the previous dose.

Conditions

  • Opioid Use Disorder

Interventions

  • naltrexone implantDrug

    3.6 g per implant set each containing 60% naltrexone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse Events (TEAEs)Time frame: time from from placement of first implant set until end of study at 60 weeks.
  2. Adverse Events of Special Interest (AESI)Time frame: time from from placement of first implant set until end of study at 60 weeks.
  3. DeathsTime frame: time from from placement of first implant set until end of study at 60 weeks.
  4. Serious Adverse Events (SAEs)Time frame: time from from placement of first implant set until end of study at 60 weeks.
  5. Adverse events (AEs) causing study discontinuationTime frame: time from from placement of first implant set until end of study at 60 weeks.
  6. Opioid overdose eventsTime frame: time from from placement of first implant set until end of study at 60 weeks.
  7. Laboratory abnormalitiesTime frame: time from from placement of first implant set until end of study at 60 weeks.
  8. SuicidalityTime frame: time from from placement of first implant set until end of study at 60 weeks.
  9. Concomitant medicationsTime frame: time from from placement of first implant set until end of study at 60 weeks.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.